Induction of remission
The first stage of treatment, aimed at calming a flare and getting Crohn's under control.
Also called: inducing remission, getting into remission, calming a flare
Related words maintenance of remission remission induction
The first stage of treatment, aimed at calming a flare and getting Crohn's under control.
Also called: inducing remission, getting into remission, calming a flare
Related words maintenance of remission remission induction
Crohn's usually comes and goes. Crohn's & Colitis UK describes remission as a time when Crohn's is well controlled, you feel better and tests show less inflammation, although some symptoms like tiredness may linger. A flare-up (also called a relapse or active disease) is when symptoms return and tests show the gut is inflamed. The NHS says a flare can last from a few days to several months.
Sources
Steroids such as prednisolone work well for calming a flare, but they cause side effects that become more likely the longer you take them. Crohn's & Colitis UK lists effects such as mood changes, sleep problems, skin changes and stomach problems. Cochrane reviews show steroids help bring Crohn's into remission, but budesonide does not keep it in remission long term. The 2025 BSG guideline warns against long or repeated steroid courses.
Sources
It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.
Sources
The Crohn's Disease Activity Index (CDAI) is an older, longer score. It needs a 7-day symptom diary, your weight and a blood test result, so it takes more effort to work out. A CDAI under 150 is taken as a marker of remission and over 450 as a marker of severe Crohn's. The Harvey-Bradshaw Index is a simpler score based on just the previous day's symptoms and does not need a blood test.
Sources
Fatigue is one of the commonest Crohn's symptoms. Crohn's & Colitis UK says it affects around 7 in 10 people during a flare and around 4 in 10 in remission, and has many possible causes. Anaemia from blood loss or poor absorption is one of them, so a blood test is worth asking about. A Cochrane review found only weak evidence so far for specific fatigue treatments.
Sources
NICE's guideline for the NHS in England on managing Crohn's in children, young people and adults. It covers giving people information and support, treatment to bring Crohn's under control and keep it there, surgery, keeping remission after surgery, checking bone health, and pregnancy. It is about care after diagnosis rather than how Crohn's is diagnosed.
Topics About Crohn's disease Medicines Surgery Monitoring Pregnancy and fertility Children and young people Steroids Immunosuppressants
Jargon explained remission inducing remission maintaining remission osteopenia NICE guideline induce remission maintain remission glucocorticosteroid thiopurine TPMT resection stricture
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
A Cochrane review confirming standard steroids are effective for bringing active Crohn's into remission. They cause more side effects than placebo, and more research was needed on the best length of treatment and how to reduce them.
Jargon explained corticosteroids induction tapering
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics Biologics and newer medicines Research
Jargon explained combination therapy purine analogue biosimilar CT-P13
Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.
Topics Biologics and newer medicines
Jargon explained induction phase 3 trial endoscopic response
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics Biologics and newer medicines
Jargon explained IL-12/23 induction certainty of evidence
Budesonide, a steroid that acts mainly in the gut, works better than placebo for bringing on remission. It is a bit less effective than standard steroids such as prednisolone, especially for severe or widespread colon disease, but causes fewer side effects and less suppression of the body's own steroid production.
Jargon explained budesonide corticosteroid adrenal suppression conventional steroids
Compares liquid-only feeding (EN) with steroids for settling a Crohn's flare. Very low-quality evidence suggests steroids may work better in adults, while liquid feeds may work better in children. The type of formula did not seem to matter. The reviewers suggest EN for children, and for adults who can manage it or need to avoid steroids.
Topics Diet and nutrition Steroids Children and young people Research
Jargon explained enteral nutrition polymeric formula elemental diet nasogastric tube elemental feed polymeric feed
Cochrane found only two small trials of probiotics ('good bacteria' supplements) for active Crohn's. The evidence is very uncertain, so we do not know whether probiotics help or are safe for this purpose.
Topics Diet and nutrition Medicines
Jargon explained probiotic very low certainty evidence
A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.
Topics Diet and nutrition Research
Jargon explained remission exclusion diet randomised controlled trial
Mesalazine-type drugs (aminosalicylates) are widely used for ulcerative colitis, but this review found little evidence that they work for active Crohn's. Low and high doses of mesalazine were not clearly better than placebo. Some trials comparing high-dose mesalazine with budesonide gave mixed results.
Topics Medicines
Jargon explained aminosalicylate 5-ASA mesalazine
Looks at methotrexate for Crohn's that has not settled with other treatment. The trials of methotrexate by mouth were small, and adding methotrexate to infliximab did not seem to add benefit, though those studies were small too. More research is needed.
Topics Immunosuppressants
Jargon explained refractory methotrexate immunomodulator